AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30642381
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine collaborative care (TCMCMC) including standard TCM history taking, physical examination, acupuncture (10 sessions of 30 minutes each), and TCM non-pharmacological advice in addition to usual rheumatologic care.
Trial: 28713486
Drug: Concurrent aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent aerobic and resistance training (3 times a week for 16 weeks)
Trial: 28713486
Drug: Concurrent aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent aerobic and resistance training
Trial: 20031007
Drug: Olopatadine (OLO)
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine (OLO) nasal spray 0.6% (1 or 2 sprays/nostril, b.i.d.)
Trial: 20031007
Drug: Olopatadine (OLO)
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine (OLO) nasal spray 0.6% (1 spray/nostril, b.i.d.)
Trial: 20031007
Drug: Olopatadine (OLO)
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine (OLO) nasal spray 0.6%
Trial: 17916225
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg/day)
Trial: 9560030
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at 0.1 IU/kg/d, n=16
Trial: 9560030
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at 0.2 IU/kg/d, n=20
Trial: 9560030
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment), n=12
Trial: 7882702
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg zuclopenthixol
Trial: 7882702
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zuclopenthixol
Trial: 7882702
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg zuclopenthixol
Trial: 7882702
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg to 20 mg daily zuclopenthixol (flexible dosing)
Trial: 3065661
Drug: Thymopentin and
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin and Hevac B Pasteur vaccine (3 doses of 5 micrograms s.c. each of vaccine at monthly intervals and 12 doses of 50 mg s.c. of thymopentin on alternate days between the first and the second vaccination)
Trial: 3065661
Drug: Hevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hevac B Pasteur vaccine (3 doses of 5 micrograms s.c. each of vaccine at monthly intervals)
Trial: 3065661
Drug: Hevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hevac B Pasteur vaccine (3 doses of 10 micrograms s.c. each of vaccine at monthly intervals)
Trial: 24561548
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg b.d. (with dose reduction to 2.5 mg b.d. for certain patients)
Trial: 15625256
Drug: Priming group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priming group (rocuronium 0.06 mg x kg(‐1) followed by 0.54 mg x kg(‐1) three minutes later)
Trial: 15625256
Drug: Bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus group (rocuronium 0.6 mg x kg(‐1))
Trial: 11786451
Drug: Aspirin (75-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75-150 mg daily)
Trial: 11786451
Drug: Intravenous glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycoprotein IIb/IIIa antagonist added to aspirin
Trial: 10468203
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 1200 mg twice daily
Trial: 10468203
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 1800 mg thrice daily
Trial: 10468203
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (combined ALA groups)
Trial: 7618455
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg, single oral dose)
Trial: 7618455
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg, single oral dose)
Trial: 2756910
Drug: Carbohydrate infusion
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate infusion
Trial: 2756910
Drug: Protein infusion
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein infusion
Trial: 2756910
Drug: Mixed meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meal infusion
Trial: 2756910
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution
Trial: 27701428
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (2 g per day for 30 days)
Trial: 18799080
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) treatment (20 microg-40 microg-60 microg) administered via intravenous infusion for 3 consecutive days
Trial: 14516802
Drug: Atropine treatment
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine treatment followed by plano lens for sound eye
Trial: 14516802
Drug: Atropine treatment
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine treatment alone
Trial: 14516802
Drug: Atropine treatment
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine treatment with plano lens
Trial: 10656435
Drug: Exisulind 400
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind 400 mg p.o. twice a day
Trial: 10656435
Drug: Exisulind 300
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind 300 mg p.o. twice a day
Trial: 10656435
Drug: Exisulind 200
RxNorm normalized name: Exisulind
DrugBank: Exisulind (DB06246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind 200 mg p.o. twice a day
Trial: 10656435
Drug: Exisulind (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exisulind (all doses)
Trial: 9582639
Drug: Fixed appliance
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed appliance therapy (non-extraction)
Trial: 9582639
Drug: Fixed appliance
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed appliance therapy (extraction)
Trial: 9582639
Drug: Fixed appliance
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed appliance therapy (both groups)
Trial: 3777409
Drug: Nalbuphine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 5 mg after fentanyl
Trial: 3777409
Drug: Nalbuphine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (all doses) after fentanyl
Trial: 29183872
Drug: Low-dose endotoxin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose endotoxin challenge in lean men
Trial: 27235530
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of parathyroid hormone (PTH) for six weeks
Trial: 20528001
Drug: AZD0837 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0837 intravenous infusion
Trial: 3046820
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mixed gangliosides (Cronassial) every weekday intramuscularly for 3-4 months
Trial: 3046820
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mixed gangliosides (Cronassial) after 13-19 weeks
Trial: 3046820
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mixed gangliosides (Cronassial) after greater than 20 weeks
Trial: 3046820
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 3 months
Trial: 352763
Drug: unspecific cream
RxNorm normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unspecific cream vehicle without active agent
Trial: 352763
Drug: unspecific vehicle
RxNorm normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unspecific vehicle for clindamycin treatment
Trial: 28429905
Drug: 25,000 IU/4-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25,000 IU/4-weekly cholecalciferol (Group A)
Trial: 28429905
Drug: 50,000 IU/4-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU/4-weekly cholecalciferol (Group B)
Trial: 28429905
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (25,000 IU and 50,000 IU)
Trial: 25566749
Drug: Single rhTSH
RxNorm normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single rhTSH administration after two weeks of T3 therapy followed by one week of THW (Group I)
Trial: 25566749
Drug: Standard stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard stimulating protocol via rhTSH injections for two consecutive days (Group II)
Trial: 24236673
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (four most commonly prescribed)
Trial: 21208151
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl ODT
Trial: 17848873
Drug: Caffeine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (oral and intravenous) for PDPH prophylaxis
Trial: 17848873
Drug: Caffeine (oral)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (oral) for PDPH treatment
Trial: 17848873
Drug: Caffeine (IV)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (IV) for PDPH treatment (from quasirandomized and open-label trials)
Trial: 17848873
Drug: Caffeine as
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine as an antinociceptive agent for PDPH
Trial: 8090093
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at L2/3 over 15 sec
Trial: 8090093
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at L4/5 over 15 sec
Trial: 8090093
Drug: Injection at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection at L2/3 over 30 sec
Trial: 3407611
Drug: 170 mg
RxNorm normalized name: mannitol 170 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 170 mg alpha‐tocopherol acetate
Trial: 27299514
Drug: Active Bright
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Bright Light Therapy (BLT) at 10,000 lux for 45 minutes daily for 2 weeks
Trial: 27299514
Drug: Control Bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Bright Light Therapy (BLT) at approx. 100 lux for 45 minutes daily for 2 weeks
Trial: 26591394
Drug: Combined aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined aspirin and dipyridamole
Trial: 23034468
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 mg with candesartan 8 mg
Trial: 23034468
Drug: Chlorthalidone (CTD)
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (CTD) 12.5 mg with candesartan 8 mg
Trial: 9495423
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral placebo and i.m. midazolam and atropine)
Trial: 3289837
Drug: Chest physical
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest physical therapy alone (group 1)
Trial: 26060295
Drug: Maraviroc (MVC)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc (MVC) 150 mg once daily
Trial: 29933096
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Trial: 16675499
Drug: Leg exercise
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leg exercise (L) in upright position
Trial: 16675499
Drug: Combined arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined arm and leg exercise (A + L) in upright position
Trial: 16675499
Drug: Combined arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined arm and leg exercise (A + L) in supine position
Trial: 15517300
Drug: Infliximab, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab, 5 mg/kg at week 0/2/6, followed by 5 mg/kg every 6 weeks in an open study.
Trial: 11181366
Drug: Ethionamide (ETA)
RxNorm normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethionamide (ETA) administered with orange juice
Trial: 11181366
Drug: Ethionamide (ETA)
RxNorm normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethionamide (ETA) administered with food
Trial: 11181366
Drug: Ethionamide (ETA)
RxNorm normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethionamide (ETA) administered with antacids
Trial: 11181366
Drug: Ethionamide (ETA)
RxNorm normalized name: Ethionamide
DrugBank: Ethionamide (DB00609)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethionamide (ETA) administered on an empty stomach (reference)
Trial: 9310718
Drug: Fluorescence technique
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescence technique for teaching application of protective creams
Trial: 9310718
Drug: Instructive videotape
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instructive videotape for teaching application of protective creams
Trial: 8257616
Drug: Cholesterol-lowering drug
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering drug use at follow-up
Trial: 24858566
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV) administered intranasally at doses of 1×10(5), 1×10(6), or 1×10(7) TCID50
Trial: 24858566
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV) administered intranasally
Trial: 21981973
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (IST) during hospitalization
Trial: 21981973
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (IST) continued after discharge
Trial: 19682735
Drug: Non-invasive ventilation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive ventilation as rescue therapy
Trial: 17403946
Drug: Thalidomide in
RxNorm normalized name: Product containing thalidomide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide in combination with dexamethasone
Trial: 11950491
Drug: MPA at
RxNorm normalized name: crospovidone (15 mpa.s at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA at dose of 2.5 mg daily (group A)
Trial: 11950491
Drug: MPA at
RxNorm normalized name: crospovidone (15 mpa.s at 5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA at dose of 5 mg daily (group B)
Trial: 9798809
Drug: Oral pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pantoprazole 40 mg
Trial: 1996436
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran (Imferon; Fisons) - usual recommended dose
Trial: 1996436
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran (Imferon; Fisons) - two-thirds of the recommended dose
Trial: 1996436
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran (Imferon; Fisons) - both doses
Trial: 6394350
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg/day (Group A)
Trial: 6394350
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg/day (Group B)
Trial: 6394350
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release nifedipine 20 mg/day (Group C)
Trial: 20977576
Drug: Exenatide twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice-daily
Trial: 18423812
Drug: Triple RAAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple RAAS blockade (spironolactone 25 mg)
Trial: 18423812
Drug: Double RAAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double RAAS blockade (cilazapril 5 mg, telmisartan 80 mg, hydrochlorothiazide 12.5 mg)
Trial: 10080412
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 to 50 mg twice daily
Trial: 10080412
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 to 100 mg twice daily
Trial: 10080412
Drug: Carvedilol and
RxNorm normalized name: carvedilol and ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol and Metoprolol (both low dose/high dose)
Trial: 8006281
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus aspirin (150 mg once daily)
Trial: 8006281
Drug: Preadmission therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preadmission therapy with aspirin
Trial: 23767174
Drug: Propofol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (100 mg/kg/min) with remifentanil (0.25 mg/kg/min)
Trial: 23767174
Drug: Isoflurane (0.8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane (0.8% end‐tidal) with remifentanil (0.25 mg/kg/min)
Trial: 21923601
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol sulfate 2.5 mg diluted in 3 ml of normal saline
Trial: 21923601
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 ml of normal saline)
Trial: 18326600
Drug: MCT oil
RxNorm normalized name: Organic MCT Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT oil (18-24 g/d)
Trial: 16507194
Drug: Combined anaesthesia
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined anaesthesia group (1 mL kg‐1 of caudal-epidural bupivacaine 0.25%)
Trial: 16507194
Drug: Balanced anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced anaesthesia group (5 microg kg‐1 of intravenous fentanyl)
Trial: 11007389
Drug: Textured silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Textured silicone gel implants
Trial: 11007389
Drug: Smooth silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smooth silicone gel implants
Trial: 8686202
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.6-0.7 g/kg/day) and enalapril (2-10 mg/day)
Trial: 8263317
Drug: Paroxetine 20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20-30 mg
Trial: 30358715
Drug: 25‐mug 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐mug 17beta‐estradiol vaginal tablets (Vagifem)